Hannah Blake pharmaphorum Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement ...

The definition of healthcare has become incredibly diverse since the turn of the century. It feels like it used to be quite simple – it was about a linear relationship between patients, doctors ...

A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind to a ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries ...

Roche is petitioning the US administration for an exemption from tariffs for pharmaceuticals, arguing there is no trade imbalance in its US business.

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie.

Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As clinical trials advance, Ben Hargreaves finds the technology is poised to ...

NICE technology appraisals for cancer drugs are often delayed - but who's really to blame? This post investigates how the DHSC contributes to hold-ups in access to innovative cancer treatments.

The US has launched a national security probe into the national security implications of importing pharmaceuticals, seen as a precursor to tariffs.

Shares in Applied Therapeutics have lost more than 80% of their value after the FDA turned down its marketing application for lead drug govorestat as a treatment for galactosaemia. The sell-off ...

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on display – EGFR ...